Expert Ratings For Insulet
Portfolio Pulse from Benzinga Insights
Insulet (NASDAQ:PODD) has been analyzed by 7 analysts, showing a range of opinions. The average 12-month price target is $213.29, with a high of $250 and a low of $162, marking a 13.71% decrease in the average target. Analysts from firms like Baird, Morgan Stanley, Piper Sandler, JP Morgan, Leerink Partners, and Jefferies have adjusted their ratings and price targets. Insulet's financials show strong revenue growth and ROE, but a high debt-to-equity ratio and below-average net margin.
December 21, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Insulet's average price target has been reduced by 13.71%, indicating a negative shift in analyst sentiment. Despite strong revenue growth and ROE, concerns about high debt and low net margin may impact the stock.
The reduction in the average price target suggests that analysts are less optimistic about Insulet's future stock performance. The strong revenue growth and ROE are positive indicators, but the high debt-to-equity ratio and below-average net margin may raise concerns about the company's financial health, potentially leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100